Tom Hals

(Reuters) – Bayer AG After a jury in California found Roundup was not an important cause of rare non-Hodgkin’s lymphoma in a child, the company announced Tuesday that it won the first Roundup trial.

Destiny Clark said that Ezra Burkitt developed lymphoma following exposure to Roundup, which she used on her family’s weeds.

Clark sued Monsanto Bayer (OTC): Bayer owned (NYSE:), because she failed to warn her about the potential cancer-causing effects of Roundup.

Roundup’s verdict was the fourth in Roundup, and it is the first to be in favor of the company.

Bayer has been plagued by Roundup lawsuits since the acquisition of Monsanto’s agricultural seeds and pesticides manufacturer Monsanto for $63 billion in 2018.

Bayer released a statement saying that this verdict was in line with the decades-old science and research supporting the safety of Glyphosate (the main ingredient in Roundup).

The company stated that while we sympathize with Ezra Clark’s family, they carefully reviewed the scientific evidence and concluded that Roundup wasn’t the reason for his illness.

Clark’s attorney said that they would consider an appeal.

Fletcher Trammel said, “We’re sorry for the boy and family.” “We will be trying multiple Roundup cases across the nation over the next 12 months and are looking forward to them.”

Bayer is still appealing two of the three other verdicts, and Bayer hopes to appeal one more. Bayer’s decision could lead to the end of Roundup.

It has resolved approximately 96,000 Roundup claims of around 125,000.

Bayer’s proposal to solve future cases was rejected by a federal court in May. It would have offered compensation, but restricted the rights of individual plaintiffs to sue.